Last reviewed · How we verify
NaCl 0.9% intranasal
Normal saline solution delivered intranasally provides isotonic hydration and mechanical cleansing of nasal passages.
Normal saline solution delivered intranasally provides isotonic hydration and mechanical cleansing of nasal passages. Used for Nasal congestion and secretion management in pediatric patients, Adjunctive therapy for upper respiratory conditions.
At a glance
| Generic name | NaCl 0.9% intranasal |
|---|---|
| Also known as | NaCl 0.9% Sintetica |
| Sponsor | University Children's Hospital, Zurich |
| Drug class | Saline solution / Nasal decongestant |
| Modality | Small molecule |
| Therapeutic area | Otolaryngology / Respiratory |
| Phase | Phase 3 |
Mechanism of action
Intranasal 0.9% NaCl (normal saline) is a physiologic salt solution that matches the osmolarity of body fluids. When administered to the nasal cavity, it hydrates mucous membranes, helps clear secretions and debris, and may reduce inflammation and congestion through osmotic effects and mechanical lavage.
Approved indications
- Nasal congestion and secretion management in pediatric patients
- Adjunctive therapy for upper respiratory conditions
Common side effects
- Nasal irritation
- Epistaxis
- Local discomfort
Key clinical trials
- A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes (PHASE1)
- Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury (PHASE1)
- Directed Topical Drug Delivery for Treatment for PASC Hyposmia (PHASE2)
- Intranasal Dexmedetomidine-esketamine Administration and Postoperative Pain in Pediatric Patients (PHASE4)
- The Importance of Insulin Action in the Brain for the Immune System During Physical Activity-Overweight (NA)
- Evaluation of the Safety and Preliminary Efficacy of Neuroinduced Mesenchymal Stem Cells and Exosome Therapy in Patients With Spinocerebellar Palsy (PHASE1, PHASE2)
- Oxytocin to Treat PTSD (PHASE2)
- Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NaCl 0.9% intranasal CI brief — competitive landscape report
- NaCl 0.9% intranasal updates RSS · CI watch RSS
- University Children's Hospital, Zurich portfolio CI